Literature DB >> 18281368

Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab.

D McGonagle, A L Tan, J Madden, A C Rawstron, A Rehman, P Emery, S Thomas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18281368     DOI： 10.1093/rheumatology/kem357

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  27 in total

Review 1.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

2.  Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis.

Authors:  Konstantinos Melissaropoulos; Stamatis-Nick Liossis
Journal:  Rheumatol Int       Date:  2018-06-04       Impact factor: 2.631

Review 3.  Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.

Authors:  Elizabeth R Volkmann; Donald P Tashkin
Journal:  Ann Am Thorac Soc       Date:  2016-11

Review 4.  [Systemic sclerosis. Objectives for the treatment].

Authors:  B Maurer; M Walder; R E Gay; S Gay; O Distler
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

5.  Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab.

Authors:  Wan-Hee Yoo
Journal:  Rheumatol Int       Date:  2010-01-08       Impact factor: 2.631

6.  B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.

Authors:  Silvia Bosello; Maria De Santis; Gina Lama; Cristina Spanò; Cristiana Angelucci; Barbara Tolusso; Gigliola Sica; Gianfranco Ferraccioli
Journal:  Arthritis Res Ther       Date:  2010-03-25       Impact factor: 5.156

7.  B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis.

Authors:  Jacob M van Laar
Journal:  Arthritis Res Ther       Date:  2010-04-22       Impact factor: 5.156

Review 8.  Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets.

Authors:  Jennifer H Anolik; R John Looney; Frances E Lund; Troy D Randall; Iñaki Sanz
Journal:  Immunol Res       Date:  2009-04-07       Impact factor: 2.829

Review 9.  Challenges and opportunities in treating inflammation associated with pulmonary hypertension.

Authors:  Norbert F Voelkel; Rasa Tamosiuniene; Mark R Nicolls
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-05-04

10.  Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Athanassios C Tsamandas; Christina Kalogeropoulou; Alexandra Kazantzi; Chaido Sirinian; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2009-05-15       Impact factor: 7.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.